Development of novel diagnostic system for pancreas cancer including early stages measuring mRNA of whole blood cells

The aim of the study is the assessment of diagnostic efficacy of extracorporeal diagnostic reagent pancreatic cancer diagnosis kit whose principle is the measurement of gene expression affected in pancreatic cancer human patients. Clinical trial registration number: UMIN000020758. Development of a blood mRNA pancreatic ductal adenocarcinoma (PDAC) screening system using real-time detection PCR to detect the expression of specific genes, in order to discriminate PDAC from healthy volunteers. We performed a clinical study to assess the performance of the developed system. We collected whole blood RNA from PDAC patients and non-cancer subjects. The sensitivity of the system for PDAC diagnosis and the specificity for non-cancer volunteers were determined for the evaluation of the screening system. Contributed by Hokuriku Liver Study Group